Sunday 18 October 2026
Export FENC’s income statement to Excel — free account
Adherex Technologies Inc.
FENC Healthcare Biotechnology
Adherex Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 million, down 6.09% from fiscal 2024. In the quarter to June 2026, revenue grew 85.2%, EPS grew 154.6% and free cash flow grew 101.4%, each against the same quarter a year earlier.
9.98
0.37
−3.57%
Follow FENC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
6.27 | 4.14 | 4.93 | 6.73 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
7,427.18 | 88.76 | (36.91) | 174.84 | |
P/B ratio |
8.75 | 5.60 | 6.20 | 0.00 | |
Price to Tangible BV |
8.75 | 5.60 | 6.20 | 0.00 | |
EV/Sales |
5.88 | 3.71 | 4.52 | 6.64 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(170.82) | (32.78) | (16.16) | (32.24) | |
EV/FCF |
(170.82) | (32.78) | (16.16) | (32.24) | |
Quick Ratio |
5.21 | 6.15 | 5.71 | 4.21 | |
Current Ratio |
5.85 | 6.98 | 6.37 | 4.69 | |
Net Debt/EBITDA |
(23.41) | 432.03 | 14.72 | 25.44 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 36.76% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | (4.03) | |
Asset Turnover |
0.98 | 0.86 | 0.77 | 0.72 | |
Operating CF/Net income |
0.03 | 11.84 | 1.25 | (2.34) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
579.00 | (17.00) | (8.29) | (0.32) | |
Research and Development Expense of Revenue |
0.66% | 0.32% | 0.15% | 0.23% | |
Selling, General and Administrative Expense of Revenue |
85.59% | 96.69% | 105.58% | 95.99% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
9.93% | 6.55% | 18.31% | 17.81% | |
Graham Net Nets |
0.11 | 0.16 | 0.15 | (0.03) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.91 | |
Earnings Yield |
(1.15%) | (4.78%) | (4.42%) | (2.46%) | |
Free Cash Flow Yield |
(0.55%) | (2.74%) | (5.67%) | (3.06%) | |
Revenue per Share |
0.52 | 0.44 | 0.48 | 0.45 | |
Operating CF per Share |
0.00 | 0.07 | (0.21) | 0.05 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.07 | (0.21) | 0.05 | |
Cash per Share |
1.19 | 1.17 | 1.29 | 0.79 | |
Shareholders Equity per Share |
1.23 | 1.10 | 1.24 | (0.16) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.23 | 1.10 | 1.24 | (0.16) | |
Free Cash Flow |
0.05 | 2.38 | (5.96) | 1.49 | |
Working Capital |
60.11 | 57.29 | 56.53 | 36.25 | |
Net Current Asset Value |
39.19 | 32.73 | 31.96 | (7.69) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
20.38 | 17.11 | 18.05 | 16.13 | |
Average Payables |
5.73 | 5.78 | 3.94 | 4.87 | |
Average Inventory |
2.29 | 1.63 | 1.31 | 1.80 | |
Average Assets |
60.31 | 59.11 | 57.75 | 54.09 | |
Average Common Equity |
17.49 | 15.90 | 14.80 | (4.83) |
Columns are period end dates